Targeting fatty acid synthase suppresses tumor development in NF2/CDKN2A-deficient malignant pleural mesothelioma
Sivasundaram KarnaniD, Akinobu OtaiD, Muhammad Nazmul HasaniD, Hideki MurakamiiD, Md Lutfur RahmaniD, Md WahiduzzamaniD, Md Towhid Ahmed Shihan, Nushrat Jahan, Lam Quang Vu, Ichiro HanamuraiD, Akihito InokoiD, Miho RikuiD, Hideaki Ito, Yoshifumi Kaneko, Yinzhi LiniD, Toshinori HyodoiD, Hiroyuki KonishiiD, Shinobu TsuzukiiD, Yoshitaka HosokawaiD
Abstract
Malignant pleural mesothelioma (MPM) is an uncommon yet deadly cancer linked to asbestos exposure. The lack of effective early diagnosis and treatment leads to reduced life expectancy among patients with MPM. This study is aimed to identify a novel molecular target inhibitor to develop more effective therapeutics for MPM. Our drug screening assay showed that the fatty acid synthase (FASN) inhibitor cerulenin demonstrates strong and selective anti-proliferative properties against NF2/CDKN2A(p16)-deficient MPM cells, surpassing the effects of cisplatin or pemetrexed. FASN protein is frequently detected in NF2/p16-deficient MPM tumor-derived tissues (15/15, 100%), but rarely in NF2/p16-intact MPM tumors (8/25, 32%). Notably, cerulenin administration successfully reduced the growth of NF2/p16-deficient MPM tumors in xenografted mice. Cerulenin inhibits mitochondrial fission by targeting dynamin-related protein 1 (DRP1) in NF2/p16-deficient cells. Moreover, the disruption of the FASN gene leads to increased ubiquitination of DRP1. These findings suggest that FASN might play a role in the tumorigenesis of MPM cells through the regulation of mitochondrial dynamics. This research offers a novel perspective on the potential development of precision medicine for MPM.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 3
- FWCI
- 4.33
- Field percentile
- top 7%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Inactivation of p21-Activated Kinase 2 (Pak2) Inhibits the Development of Nf2-Deficient Malignant Mesothelioma
E. Sementino, Y. Kadariya, … J. R. Testa·bioRxiv·Jun 30, 2020
- Suppression of de novo lipogenesis and dietary PUFA supplementation inhibit prostate cancer progression
Silvia Daniele Rodrigues, Caroline F. Ribeiro, … Massimo F. Loda·bioRxiv·Sep 21, 2026
- Dual inhibition of SHP2 and autophagy suppresses NF1-associated Malignant Peripheral Nerve Sheath Tumors
S. Farouk Sait, K.-h. Tang, … L. F. Parada·bioRxiv·Aug 18, 2022
- Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of malignant pleural mesotheliomas to CDK4/6 inhibition
S. Paternot, E. Raspe, … P. P. Roger·bioRxiv·Apr 11, 2022
- Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma
E. Aliagas, A. Alay, … E. Nadal·bioRxiv·Feb 8, 2021
- Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer
C. Bartolacci, C. Andreani, … P. P. Scaglioni·bioRxiv·Mar 18, 2021